Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)

SHA:688513 Revenue

Chengdu Easton Biopharmaceuticals had revenue of 326.26M CNY in the quarter ending March 31, 2026, with 6.75% growth. This brings the company's revenue in the last twelve months to 1.35B, up 0.87% year-over-year. In the year 2025, Chengdu Easton Biopharmaceuticals had annual revenue of 1.33B, down -1.36%.

• Revenue (ttm): 1.35B
• Revenue Growth: +0.87%
• P/S Ratio: 5.80
• Revenue / Employee: 913.52K
• Employees: 1,480
• Market Cap: 7.85B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.33B	-18.37M	-1.36%
Dec 31, 2024	1.35B	232.63M	20.82%
Dec 31, 2023	1.12B	-53.39M	-4.56%
Dec 31, 2022	1.17B	147.58M	14.43%
Dec 31, 2021	1.02B	101.02M	10.96%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 19, 2026

Data Sources Report a data error